Pseudotyped Luciferase rSARS-CoV-2 Spike for pseudovirus luciferase assay (PVLA)
Quercetin self-assembly nanoparticles with antiviral molecules are effective in inhibiting SARS-CoV-2 pseudovirus infection
Figure 1. Wuhan recombinant rSARS-CoV2 pseudovirus neutralization test. | Product Name | Cat. No. | Applications | Host Species | Datasheet | Price | Add to Basket |
|---|
| Product Name | Cat. No. | Applications | Host Species | Datasheet | Price | Add to Basket |
|---|
The spiny (S) protein of coronaviruses participates in and catalyzes the first critical step of viral infection, acts as the primary antigen modifying the surface of viral particles and induces neutralizing antibody responses, and is an important target for diagnostic, therapeutic, and vaccine development. SARS-CoV-2 S glycoprotein is a highly glycosylated type I membrane protein in a trimeric form that is anchored to the viral membrane by a transmembrane fragment with a large extracellular structural domain that can be used to modify the viral surface. S proteins promote membrane fusion by binding to the receptor angiotensin-converting enzyme 2 (ACE2) on host cells and undergoing structural rearrangements. The full length of the S protein of the original strain contained 1273 amino acid residues, including the N-terminal signal peptide, the receptor-binding fragment S1, and the fusion fragment S2. S1 can be further divided into the N-terminal domain (NTD), the receptor-binding domain (RBD), and the C-terminal domains (CTD1 and CTD2), and S2 can be divided into the fusion peptide (FP), fusion-peptide proximal region (FPPR), heptad repeat sequence 1 (HR1), center helix (CH), connector domain (CD), heptad repeat sequence 2 (HR2), transmembrane segment (TM) and cytoplasmic tail (CT).
Prior to fusion, the S1 fragment adopts a "V"-shaped structure, with NTD as one arm and RBD, CTD1, and CTD2 as the other arms, which surround the central helical bundle of S2 so that the N-terminus of HR1 protrudes toward the viral membrane. The three RBDs form the apex of the trimer, which is divided into two different conformations depending on whether or not it is in contact with the receptor. The three NTDs are located at the periphery of the trimer, each in contact with the RBD of the neighboring protomer. CTD1 and CTD2, located below the RBD and S2 and between the two neighboring NTDs, regulate these structural domains and play an important role in the structural rearrangements required for membrane fusion. After fusion S1 dissociates as a monomer and S2 HR1 flips to form a continuous long helix with CH, which is further surrounded by a short helix and β-fold at the distal end of the membrane.
Figure 1. Distinct conformational states of the SARS-CoV-2 spike protein
(Source: Zhang J, et al. 2021)
The S protein is a key component of the first-generation COVID-19 vaccine, however, with the global epidemic of the outbreak and the increased number of viral replicates, S protein mutations are increasing at a significant rate, and are likely to occur more frequently due to selective pressure from host immunity gained from previous infections and vaccinations. Many emerging and surviving mutants enhance the function of novel coronaviruses in terms of infectivity and immune escape, posing greater challenges for vaccine development.
Pseudotyped Luciferase rSARS-CoV-2 S
References
1. Zhang J, et al. Structure of SARS-CoV-2 spike protein. Curr Opin Virol. 2021 Oct;50:173-182.
2. Magazine N, et al. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses. 2022 Mar 19;14(3):640.
Q: Approximately how many neutralization assays can be completed from one tube of virus?
A: Recommended Input: 10-30 uL (lot specific) virus per well (96-well plate) using the ACE2/293T stable cell line.
Q: Do you use VSV or Lenti virus for pseudotyping?
A: Pseudotyped Luciferase rSARS-CoV-2 Spike (COV-PS01) are produced in HEK-293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene.
We can also provide VSV based SARS-CoV-2 spike pseudovirus with mcherry as a reporter gene (CD Cat# COV-PSV10).
Q: I want to know about virus strain in pseudotype virus to choose proper antibodies.
A: The spike protein in this pseudotype virus is from the strain Wuhan-Hu-1.
We can provide Mouse Anti-SARS-CoV-2 Spike Neutralizing Antibodies with Cat# CABT-CS064 and CABT-CS065.
Q: Is it the full length spike being expressed?
A: Yes, It is a full-length Spike
Q: We would like to know if the pseudovirus carries N and/or M proteins.
A: The Pseudotyped Luciferase rSARS-CoV-2 Spike does not carry SARS-CoV-2 N and M proteins.
Predictive Modeling on the Number of Covid-19 Death Toll in the United States Considering the Effects of Coronavirus-Related Changes and Covid-19 Recovered Cases
INTERNATIONAL JOURNAL OF MATHEMATICAL ENGINEERING AND MANAGEMENT SCIENCES
Authors: Hoang Pham
COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
VACCINE
Authors: Roncati, Luca; Vadala, Maria; Corazzari, Veronica; Palmieri, Beniamino